USFDA advisory committee votes against approval of Novartis’ RLX030
RLX030 is under review to improve the symptoms of AHF through reduction of the rate of worsening of heart failure
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.